CFC-powered inhalers inclusion in FDA reform bill agreed to by Sen. Kennedy.
This article was originally published in The Gray Sheet
Executive Summary
SEN. KENNEDY TO SUPPORT INCLUSION OF CFC-POWERED INHALERS BILLS IN S 830 during conference of the FDA reform bill. The Massachusetts Democrat is understood to be willing to accept the inclusion of Sen. Tim Hutchinson's (R-Ark.) S 1299, and its companion legislation in the House, Rep. Mark Foley's (R-Fla.) HR 2627, which would prevent FDA from banning metered-dose inhalers for asthma which use chlorofluorocarbons as the propellant until acceptable alternative products are available.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.